^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FOLR1 expression

    i
    Entrez ID:
    2348
    Related biomarkers:
    Expression
    Related tests:
    Apply
    Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (SL03-OHD-105) (NCT05483933)
    Phase 1
    Shattuck Labs, Inc.
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    08/18/2022
    Primary completion :
    02/07/2025
    Completion :
    02/07/2025
    FOLR1
    |
    FOLR1 expression
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer (NCT05456685)
    Phase 2
    AbbVie
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    09/28/2022
    Primary completion :
    05/12/2026
    Completion :
    05/12/2026
    FOLR1 • BRCA
    |
    FOLR1 expression
    |
    carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma (ZOLAR) (NCT06537596)
    Phase 1
    Telix Pharmaceuticals (Innovations) Pty Ltd
    Recruiting
    Last update posted :
    12/19/2024
    Initiation :
    10/31/2024
    Primary completion :
    03/01/2026
    Completion :
    08/01/2026
    PDGFRA
    |
    FOLR1 expression
    |
    Lartruvo (olaratumab)
    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) (NCT05445778)
    Phase 3
    ImmunoGen, Inc.
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    12/27/2022
    Primary completion :
    03/01/2027
    Completion :
    04/01/2029
    FOLR1 • BRCA • MUC16
    |
    FOLR1 expression • MUC16 elevation
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    PRO1184 for Advanced Solid Tumors (PRO1184-001) (NCT05579366)
    Phase 1/2
    ProfoundBio US Co.
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    12/07/2022
    Primary completion :
    10/01/2025
    Completion :
    04/01/2026
    HER-2 • FOLR1
    |
    HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Rina-S (rinatabart sesutecan)
    Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) (NCT05041257)
    Phase 2
    ImmunoGen, Inc.
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    08/31/2021
    Primary completion :
    01/17/2024
    Completion :
    12/13/2024
    FOLR1 • BRCA
    |
    FOLR1 expression • BRCA mutation
    |
    Elahere (mirvetuximab soravtansine-gynx)
    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (NCT05870748)
    Phase 2/3
    Sutro Biopharma, Inc.
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    07/12/2023
    Primary completion :
    09/01/2025
    Completion :
    02/01/2026
    FOLR1
    |
    FOLR1 expression • FOLR1 positive
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
    A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (ELU-FRα-1) (NCT05001282)
    Phase 1/2
    Elucida Oncology
    Recruiting
    Last update posted :
    03/28/2024
    Initiation :
    09/13/2021
    Primary completion :
    06/15/2024
    Completion :
    06/15/2025
    FOLR1
    |
    FOLR1 expression
    |
    ELU001
    Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection (NCT05378737)
    Phase 1
    Bio-Thera Solutions
    Recruiting
    Last update posted :
    12/22/2023
    Initiation :
    07/06/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    FOLR1
    |
    FOLR1 expression
    Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT04606914)
    Phase 2
    University of Alabama at Birmingham
    Recruiting
    Last update posted :
    11/30/2023
    Initiation :
    05/27/2021
    Primary completion :
    05/31/2026
    Completion :
    05/31/2028
    BRCA
    |
    FOLR1 expression
    |
    carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) (NCT04209855)
    Phase 3
    ImmunoGen, Inc.
    Active, not recruiting
    Last update posted :
    03/06/2023
    Initiation :
    12/31/2019
    Primary completion :
    09/01/2023
    Completion :
    04/01/2024
    FOLR1
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal
    Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer (NCT02593227)
    Phase 2
    Marker Therapeutics, Inc.
    Completed
    Last update posted :
    07/19/2021
    Initiation :
    04/01/2016
    Primary completion :
    07/15/2021
    Completion :
    07/15/2021
    HER-2 • FOLR1
    |
    FOLR1 expression
    |
    cyclophosphamide • TPIV200 • cyclophosphamide intravenous
    A Study of MORAb-003 in Patients With Solid Tumor (MORAB-003-J081-102) (NCT01049061)
    Phase 1
    Eisai Co., Ltd.
    Completed
    Last update posted :
    06/11/2020
    Initiation :
    01/01/2010
    Primary completion :
    01/01/2013
    Completion :
    02/01/2013
    FOLR1
    |
    FOLR1 expression
    |
    farletuzumab (MORAB-003)